Linked Life Data

12089482

Source:http://linkedlifedata.com/resource/pubmed/id/12089482

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2002-6-28
pubmed:abstractText
This article reviews the literature on breast imaging with [18F]fluorodeoxyglucose positron emission tomography (FDG PET). In clinical applications, there is currently no defined role for detecting primary breast cancer. The limited sensitivity of FDG PET does not allow the exclusion of malignancy, in particular small breast carcinomas, micrometastases and small, tumour infiltrated lymph nodes. However, in advanced stages, PET accurately determines the extent of disease, including the loco-regional lymph node status. Furthermore, whole-body PET imaging promises a high diagnostic accuracy for detecting recurrent or metastatic breast carcinoma. Future clinical applications may include monitoring therapeutic effects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0143-3636
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
613-8
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Positron emission tomography for the diagnosis of breast cancer.
pubmed:affiliation
Department of Nuclear Medicine, Technische Universität München, Munich, Germany.
pubmed:publicationType
Journal Article, Review